The role of Coenzyme Ubiquinone CoQ10 in modulating the changes induced by the antidepressant Venlafaxine in albino rats fetuses

Abu Gabal, H* and Al Shabanat, F**
* College of Science and Humanities, Soliman Bin Abdul Aziz University.
** College of Science, Princess Nora Bent Abdul Rahman University.

Abstract

Aim of the work: The present study was done to investigate the role played by CoQ10 in the control of the morphological and histological changes induced in the fetuses of rats injected by the antidepressant Venlafaxine.

Material and methods: 70 pregnant Wister wister rats were injected intraperitonealy during the organogenesis period with the antidepressant Venlafaxine (0.25mg /100g.body weight) on day 7 of gestation. Mean number of alive embryos, weight and length of them were recorded with the noticeable malformations beside maternal weights. The protective role of CoQ10 (0.6 mg. /100g. body weight) was also detected.

Results: Venlafaxine injection induced a very highly significant decrease in the mean maternal and fetal body weights, the two horns of the uteri appeared unequal as well as the fetuses were unequally distributed between them, beside the appearance of a lot of resorbed bodies into them, also fat sacs were clear, a case of ectopic pregnancy was obvious, as well as very highly significant decrease in the mean number of alive fetuses was noticed, fetal growth retardation beside lots of rat fetal malformations were observed such as subcutaneous blood bleeding, cleft lips and anomalies of the fore and hind limbs as well as kyphosis of the body.

Intraperitonealy injection of Venlafaxine by the fractionated dose (0.75mg. /100g body weight) on days 7, 10 and 13 of gestation 0.25mg. /100g each resulted in the death of all the pregnant rats. CoQ10 (0.6 mg. /100g. body weight) orally injected to the pregnant rats before Venlafaxine treatment at the two doses (0.25 and 0.75mg./100g.body weight) improved the above morphometric and morphological as well as the skeletal system changes.

Conclusion: CoQ10 (0.6 mg. /100g. body weight) orally injected to the pregnant rats treated with Venlafaxine showed protective effect against the dangerous changes induced by this antidepressant.

Introduction

An antidepressant is a psychiatric medication used to alleviate mood disorders, such as major depression, dysthymia and anxiety disorders (Smith et al., 2010). Drugs including the monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) are most commonly associated with the term (Rubino et al., 2007). These medications are among those most commonly prescribed by psychiatrists and other physicians, their effectiveness and adverse effects are the subjects of many studies and competing claims (Tiilhonen et al., 2006).

The management of depression in pregnancy is complex, as it is based on balancing the risks with the benefits of treatment versus no treatment for both the mother and the fetus. Studies have shown that exposure to mental illness in pregnancy has deleterious short-term and long-term effects for the exposed mother and fetus (Dimidjian et al., 2009; Raudzus and Misri, 2009). On the other hand, untreated depression during pregnancy has been
The role of.....

associated with miscarriage, perinatal complications and increased admissions to neonatal intensive care. Depression that is not treated during pregnancy can be associated with premature birth and low birth weights (Yonkers, 2009). Venlafaxine is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is prescribed for the treatment of clinical depression and anxiety disorders (Adan-Manes et al., 2006). However, treatment of pregnant women with Venlafaxine induced developmental toxicities including spontaneous abortions, prematurity, fetal growth retardation, neonatal serotonin syndrome, neonatal behavioral syndrome such as withdrawal and respiratory distress (Simon et al., 2002; Hendrick et al., 2003). On the other hand, Venlafaxine treatment was consistently associated with higher risk of mothers suicidal ideation compared with other SSRIs (Rubino et al., 2007; Wogelius, et al., 2007; Salvatore, 2008). Källén and Olausson (2007) found that maternal use of selective serotonin re-uptake inhibitors (SSRIs) has been associated with an increased risk of infant malformations such as cystic kidneys, cardiovascular defects as ventricular and atrial septum defects as well as craniostenosis or omphalocele. Neonatal behavioral signs included central nervous, respiratory, and digestive systems, as well as hypoglycemia and vomiting, tachycardia, and jaundice in the exposed group were reported by Wan (2007).

CoQ10 is a naturally occurring compound found in every cell in animal organisms and in humans. It plays a key role in mitochondrial bioenergetics, it is also extensively investigated to play antioxidant role in preventing the generation of free radicals as well as oxidative modifications of proteins, lipids, and DNA (Siemieniuk and Skrzydlewska, 2005; Littarru and Tiano, 2007; López et al., 2010). These compounds could potentially play a role in the treatment of mitochondrial disorders, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, and other conditions of neurodegenerative and neuromuscular disorders (Mancuso et al., 2010). Quinzii et al., (2010) found that CoQ 10 deficiency caused variable defects of ATP synthesis and oxidative stress.

There is a relationship between CoQ 10 and fetal development, Haruna et al. (2010) concluded that the level of maternal CoQ10 is positively associated with fetal growth, as well as balanced rapid metabolic changes during pregnancy. Bentov et al. (2010) cited that the use of mitochondrial nutrients improve the outcome of reproductive dysfunction.

Material and Methods:

70 Wister wister mature virgin female rats (160-180g. body weight) were used in the present work and 35 males for mating. The rats were obtained from King Faisal specialist hospital research centre. The animals were kept under adequate dietary, ventilation and humidity conditions. Pregnancy was ascertained by daily examinations of vaginal smears (Taylor, 1986). The experimental animals were divided into 3 main groups:

I- The control group(normal group):
In this group the pregnant rats were injected Intraperitonealy by distilled water 0.25ml/100g. (The solvent of Venlafaxine) on days 7, 10 and 13 of gestation.

II- The experimental control groups:
a- In this group pregnant rats were orally administered with olive oil (the solvent of Co Q10) on days 7, 10 and 13 of gestation.
b- In this group animals were orally administered with CoQ10 at a dose 0.6mg./100g.body weight) on days 7, 10 and 13 of gestation.

III- The experimental groups:
a- In this group pregnant rats were injected Intraperitonealy by Venlafaxine at a dose 0.25mg./100g body weight on day 7 of gestation.
b- In this group pregnant rats were injected intraperitoneally by Venlafaxine at a dose 0.75mg /100g body weight fractionated on days 7, 10 and 13 of gestation (0.25mg /100g each).

c- In this group pregnant rats were orally administered with CoQ10 at a dose 0.6mg./100g body weight (on days 7, 10 and 13 of gestation) then injected intraperitoneally by Venlafaxine at a dose 0.25mg./100g body weight (day 7 of gestation).

d- In this group pregnant rats were orally administered with CoQ10 at a dose 0.6 mg. /100g body weight (on days 7, 10 and 13 of gestation) then injected intraperitoneal by Venlafaxine at a dose 0.75mg./100g.body weight (fractionated on days 7, 10 and 13 of gestation).

The number of the pregnant rats in all the previous treated groups is ten rats.

I- Maternal Investigations:
1- The female rats were weighed pre-gestation with Sartorius 1104.

2-Pregnant rats were weighed on days 7, 10 and 13 of gestation to evaluate the increase in the body weight due to pregnancy.

3- Observing of blood from the vaginal opening, of the pregnant female was taken as an indication of abortion.

4- The mortality rate in the different groups was illustrated.

II- Embryological Investigations:
The embryos were examined carefully for the following studies:

1-The mean number of alive, dead and malformed embryos for each group.

2- The mean body weight of live embryos using Metller balance.

3- The mean body length of live embryos was measured in cm. using a compass filament.

4-The malformed embryos were examined carefully and photographed.

5- Alizarin red S stain (Bancroft and Gamble, 2002) was used for the demonstration of the possible skeletal abnormalities.

Results

Results of the pregnant rats indicated that intraperitoneal injection of Venlafaxine at a dose 0.25mg./100g.body weight on day 7 of gestation induced a very highly significant decrease (p<0.001) in the mean maternal body weights, the uterine weights, the two horns of the uteri appeared unequal as well as the fetuses were unequally distributed between them with appearance of lots of resorbed bodies into them, also fat sacs were clear, a case of ectopic pregnancy was obvious. However Venlafaxine intraperitoneally fractionated injection (0.75mg./100g.body weight) on days 7, 10 and 13 of gestation led to the death of all the pregnant rats. Orally administration with CoQ10 (0.6mg./100g.body weight) showed improvement of all the above mentioned parameters induced by the antidepressant Venlafaxine (Figs. 1, 2 and 3 a, b, c, d & e).

Results of the fetuses showed that intraperitoneal injection of pregnant rats with Venlafaxine (0.25mg./100g.body weight) on day 7 of pregnancy induced a very highly significant decrease (p<0.001) in the number of live fetuses, fetal body weights as well as body lengths. CoQ10 orally administration to pregnant rats before Venlafaxine injection at the two doses (0.25 and 0.75mg./100g.body weight) resulted in very highly significant (p<0.001) improvement in the morphometric changes; however neither maternal deaths nor fetal deaths occurred (Figs. 4, 5&6).

Lots of malformations were observed after maternal Venlafaxine injection (0.25 mg. /100g. body weight) such as variation of the body sizes of the fetuses even of the same mother, thin and fragile fetal skin was observed, as well as congestion of blood vessels in the head and ear regions,
subcutaneous hemorrhage was observed. Malformed rostrum (cleft lips), anomalies of the fore and hind limbs as well as kyphosis of the body were noticed (Figs 7-9). The axial and peripheral fetal skeletal systems were affected as follows; increased of the number of non ossified bones in comparison to the control group (Figs. 12-14& Tables 1-4). CoQ10 injection before Venlafaxine injection (at the two doses) improved the external morphology as well as the changes in the skeletal system (Figs. 15&16&Tables 1-4).

![Fig. 1: Mean body weights (g.) of pregnant rats in the different groups on day 19 of gestation.](image)

![Fig. 2: Mean uterine weights of pregnant rats in the different groups on day 19 of gestation.](image)
Fig.3 (a): A uterus of control rat group on day 19 of gestation showing that the two horns are equal.

Fig.3 (b): A uterus of Venlafaxine treated group (0.25mg. /100g.b.w.) on day 19 of gestation the two horns are unequal(1), the fetuses were unequally distributed between them(2), as well as fat sacs are obvious(3).

Fig.3 (c): The uteri of Venlafaxine group (0.25mg. /100g.b.w.) ectopic pregnancy (1), resorbed bodies are obvious (2).
The role of....

Fig.3 (d): The uteri of the Venlafaxine group (0.025mg. /100g.b.w.) after CoQ10 injection (0.6mg. /100g.b. w.) improvements of the uterine morphology are obvious.

Fig.3 (e): The uteri of the Venlafaxine group (0.75mg. /100g.b.w.) After CoQ10 injection (0.6mg. /100 g. b.w.) Improvements of the uterine morphology are obvious.
Fig. 4: Mean number of live fetuses of the different female rat groups on day 19 of gestation.

Fig. 5: Mean body weights (gm.) of live fetuses of the different groups on day 19 of gestation.
Fig.6: Mean body lengths (cm.) of live fetuses of the different rat groups on day 19 of gestation.

Fig.7: Fetuses maternally injected with Venlafaxine (0.25mg./100g.b.w.) showing subcutaneous hemorrhage (1), subcutaneous blood vessels congestion (2a&b) and Phocomelia of the limbs (3).
Fig. 8: Fetuses maternally injected with Venlafaxine (0.25g./100g.b.w.) showing cleft lips (1), kyphosis (2), subcutaneous hemorrhage (3) and hypertrophy of the abdomen region.

Fig. 9: Fetuses maternally injected with Venlafaxine (0.25mg./100g.b.w.) showing Phocomelia of the limbs (1), cleft lips (2), subcutaneous hemorrhage (3) and fragile skin (4).

Fig. 10: Fetus of rat 19th day of gestation maternally administrated with CoQ10 then Venlafaxine injected (0.25mg. /100g.b.w.) showing improvements of the morphological features.
Fig. 11: Fetus of rat 19th day of gestation maternally administrated with CoQ10 then Venlafaxine injected (0.75mg. /100g.b.w.) show some improvements, however still some malformations appeared.

Fig. 12: Skeletal system of rat fetus 19th day of gestation, after distilled water treatment (Alizarin red S) X: 1.3.
Fig. 13: Skeletal system of rat fetus 19th day of gestation maternally administrated with Co Q10 (Alizarin red S) X: 2.4.

Fig. 14: Rat fetal skeletal system 19th day of gestation, maternally injected with Venlafaxine (0.25mg./100g.b.w.) (Alizarin red S)X: 2.8.
The role of…..

**Fig.15:** Rat fetal skeletal system 19th day of gestation, maternally administrated with CoQ10 then injected with Venlafaxine (0.25mg./100g.b.w.) (Alizarin red S)X: 1.75.

**Fig.16:** Rat fetal skeletal system 19th day of gestation, after maternally CoQ10 administration then Venlafaxine injection (0.75mg./100g.b.w.) (Alizarin red S)X: 2.28.
Table 1: Skull Bones of fetuses of different groups 19th day of gestation.
(+ ossified  (-) non-ossified

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control group (distilled water)</th>
<th>Experimental Control group (olive oil)</th>
<th>CoQ10 group</th>
<th>Venlafaxine group (0.25mg/g.b.w.)</th>
<th>CoQ10+Venlafaxine (o.25mg./g.b.w.)</th>
<th>CoQ10+Venlafaxine (o.75mg./g.b.w.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premaxilla</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Maxilla</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Nasal</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Frontal</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Parietal</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interparietal</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Squamosal</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Jugal</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Exooccipital</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Supraoccipital</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Basioccipital</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tympanicum</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 2: Fetal vertebrae of different groups 19th day of gestation.
(+ ossified  (-) non-ossified

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control group (distilled water)</th>
<th>Experimental Control group (olive oil)</th>
<th>CoQ10 group</th>
<th>Venlafaxine group (0.25mg/g.b.w.)</th>
<th>CoQ10+Venlafaxine (o.25mg./g.b.w.)</th>
<th>CoQ10+Venlafaxine (o.75mg./g.b.w.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Thoracic</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Lumbar</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Sacral</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>-</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Caudal</td>
<td>14</td>
<td>14</td>
<td>14</td>
<td>-</td>
<td>14</td>
<td>-</td>
</tr>
</tbody>
</table>
The role of…..

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control group (distilled water)</th>
<th>Experimental Control group (olive oil)</th>
<th>CoQ10 group</th>
<th>Venlafaxine group (0.25mg/g.b.w.)</th>
<th>CoQ10+Venlafaxine (0.25mg./g.b.w.)</th>
<th>CoQ10+Venlafaxine (0.75mg./g.b.w.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scapula</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Supra-Scapula</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Clavicle</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sternebrae</td>
<td>(6)+</td>
<td>(6)+</td>
<td>(6)+</td>
<td>(4)+</td>
<td>(6)+</td>
<td>(6)+</td>
</tr>
<tr>
<td>Ribs</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Humerus</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Radius</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ulna</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Meta-carpals</td>
<td>(5)+</td>
<td>(5)+</td>
<td>(5)+</td>
<td>-</td>
<td>(5)+</td>
<td>-</td>
</tr>
<tr>
<td>Phalanges of fingers</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 3: Bones of the pectoral girdle and fore-limb of fetuses of the different groups 19th day of gestation.
(+ ossified  (-) non-ossified)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control group (distilled water)</th>
<th>Experimental Control group (olive oil)</th>
<th>CoQ10 group</th>
<th>Venlafaxine group (0.25mg/g.b.w.)</th>
<th>CoQ10+Venlafaxine (0.25mg./g.b.w.)</th>
<th>CoQ10+Venlafaxine (0.75mg./g.b.w.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ileum</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ischium</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pubis</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Femur</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tibia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Fibula</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tarsus</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Meta-tarsal</td>
<td>(5)+</td>
<td>(5)+</td>
<td>(5)+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Phalanges of toes</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 4: Bones of the pelvic girdle and hind-limb of fetuses of the different groups 19th day of gestation.
(+ ossified  (-) non-ossified)
Discussion

Major depression is twice as common in women as in men (Gentile, 2005). Pregnancy and post partum period are considered to be relatively high risk times for a woman with pre-existing psychiatric illnesses, especially for depressive episodes in women (Salvatoer, 2008; Cohen et al., 2010).

Antidepressants alter the working procedure of neuro-transmitters in the body, which pass signals from one brain cell to another thus; they are needed for normal brain function. During depression some of the neurotransmitter systems, particularly those of Serotonin and Noradrenalin, don’t work properly. Antidepressants help people with depression by making these natural chemicals more available to the brain (Wan, 2007).

The present study revealed that intraperitonealy injection of pregnant rats with the antidepressant Venlafaxine (0.25mg. /100g.body weight ) on day 7 of gestation (the organogenesis period ) induced a very highly significant decrease in the mean maternal body weights these results are in agreement with those of Wessinger et al.( 2006 ) ; Wen et al.(2007) and de Abajo and Rodriguez (2008) who cited that Venlafaxine treatment induced nervousness, loss of appetite, upper gastrointestinal bleeding and body weakness(Li et al.,2011) . Moreover, a very highly significant decrease in the number of live fetuses, fetal body weights and lengths were observed in this study. These results are in agreement with those of Simon et al. (2002) , Hendrick et al. (2003) and Mawer et al.( 2010 ). Briggs et al. (2008) cited that treatment of the pregnant mothers with Venlafaxine during the second trimester induced fetal growth retardation. However, the present results showed that lots of congenital anomalies were evident such as subdermal blood bleeding, cleft lips, anomalies of the fore and hind limbs as well as kyphosis of the body.These results are in agreement with those of Källén and Olausson(2007) ; Wogelius et al. (2007)) .Kimberly and Yonkers(2009) and Wisner et al. (2009) who found increased risk of congenital malformation after exposure to antidepressants in early pregnancy. Briggs et al. (2008) found oral cleft, lung and heart defects and respiratory distress in neonates of mothers of mothers treated with Venlafaxine during pregnancy. Wan (2007) reported that neonatal behavioral signs included central nervous, respiratory, and digestive systems, as well as hypoglycemia and vomiting, tachycardia, and jaundice after exposure to SSRIs and Venlafaxine during pregnancy.

Intraperitonealy injection of pregnant rats with Venlafaxine (0.75mg. /100g.b.w. fractionated at 3 doses 0.25mg./100g body weight each) on days 7, 10 and 13 of gestation revealed the death of all the pregnant rats. CoQ10 orally injected to the pregnant rats (0.6mg./100g.body weight) before intraperitonealy injection with Venlafaxine by its two doses resulted in neither maternal death nor fetal death occurred, moreover CoQ10 revealed improvement of the morphometric, morphological, and histological changes, these results are in agreement with those of Haruna et al. (2010) and López et al.,(2010) who cited that the serum CoQ10 levels increase during pregnancy and the levels at the 3rd trimester positively associated with birth weight, they added that the increased CoQ10 during pregnancy may have protective role for fetal growth by its protective role against maternal oxidative stress during pregnancy. Quinzii et al. (2010) found that reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. Niklowitz et al. (2007) and Maes et al. (2009) cited that depressed patients may benefit from CoQ10 supplementation. The findings that lower CoQ10 is a risk factor to coronary artery disease and chronic heart failure (CHF) and mortality due to CHF, they added that...
CoQ10 supplementation induced platelet level increased, moreover a positive correlation was shown between the plasma CoQ10 level and platelet and white blood cell CoQ10 levels. During CoQ10 supplementation, it may support anti-oxidative defense mechanisms.

ACKNOWLEDGMENT
The present work was supported by KACST grant no. AT32 -16.

References


Li JJ, Yuan YG, Hou G and Zhang X (2011): Dose-related effects of Venlafaxine on PCREB and brain-derived neurotrophic factor (BDNF) in the hippocampus of the rat by chronic unpredictable stress.


stress, and cell death correlate with level of CoQ10 deficiency. FASEB. J., 24(10):3733-43.


دور الإنزيم المساعد كيو10 في تعديل التغيرات التي يحدثها مضاد الاكتئاب فينلافاكسين في أجنة الجرذان البيضاء

هناك أبوجيل،*، فوزية الشبانات**

* كلية العلوم والدراسات الإنسانية، جامعة سلمان بن عبد العزيز
** كلية التربية، جامعة سلمان بن عبد العزيز

يهدف هذا البحث إلى دراسة دور الإنزيم المساعد كيو10 في الحد من التغيرات في الشكل الظاهري كما التغيرات القياسية ومتغيرات الجهاز الهيكلي التي يحدثها عقار فينلافاكسين في أجنة الجرذان البيضاء.

أجري هذا البحث على 70 من إناث الجرذان البيضاء و35 من ذكور الجرذان البيضاء (من أجل التزاوج).

كما تم تقسيم حيوانات التجارب إلى ثلاث مجموعات رئيسية:

1- المجموعة الضابطة (المجموعة الطبيعية):

- تضم مجموعة من إناث الجرذان الحوامل تم حقنها بالماء المقطوع (المادة المذيبة لعقار فينلافاكسين) عن طريق التجويف البريتوني بمقدار 5.0 مل/200جم من وزن الجسم في اليوم السابع والعشرين والثامن عشر من الحمل (فترة تكوين الأعضاء).

2- المجموعات الضابطة التجريبية:

- مجموعة من إناث الجرذان الحوامل تم إعطائها زيت الزيتون (المادة المذيبة للإنزيم المساعد كيو10) عن طريق الفم في اليوم السابع والعشرين والثامن عشر من الحمل.
- مجموعة من إناث الجرذان الحوامل تم إعطائها الإنزيم المساعد كيو10 عن طريق الفم بجرعة مقدارها 6.0 مجم/100جم من وزن الجسم في الأيام السابع والعشرين والعشرين والثامن عشر من الحمل.

3- المجموعات التجريبية:

- مجموعة من إناث الجرذان الحوامل تم حقنها بعقار فينلافاكسين بجرعة 25.0 مجم/100جم من وزن الجسم عن طريق التجويف البريتوني في اليوم السابع من الحمل.
- مجموعة من إناث الجرذان الحوامل تم حقنها بعقار فينلافاكسين بجرعة 75.0 مجم/100جم من وزن الجسم عن طريق التجويف البريتوني مجزأة على ثلاث مرات (25.0 مجم/100جم من وزن الجسم في الأيام السابع والعشرين والثامن عشر من الحمل).
- مجموعة من إناث الجرذان الحوامل تم إعطائها العقار بجرعة 0.6 مجم/100جم من وزن الجسم ثم حقنها بعقار فينلافاكسين بجرعة 25.0 مجم.
- مجموعة من إناث الجرذان الحوامل تم إعطائها العقار بجرعة 0.6 مجم/100جم من وزن الجسم ثم حقنها بعقار فينلافاكسين بجرعة 75.0 مجم مجزأة على الأيام السابع والعشرين والثامن عشر من الحمل.

نتائج الدراسات التي أجريت على الجرذان الحوامل:

انصحت بنتائج الدراسة الحالية أن حقن الجرذان الحوامل بعقار فينلافاكسين بجرعة مقدارها 0.25 مجم/100جم من وزن الجسم أدى إلى حدوث نقص معنوي عالي جداً في متوسط أوزان الجرذان الحوامل وعدم تساوي قرنى الرحم في الطول حيث ظهر أحدهما أقصر من الآخر بالإضافة لعدم تساوي...
توزيع الأجنحة بهما وأيضاً ظهر العديد من الأجسام الممتصة بالإضافة إلى ظهور أكياس دهنية وظهور حالة حمل خارج الرحم مقارنة بالمجموعة الضابطة بينما أدت المعاملة بعقار فينلافاكسين بجرعة 0.75 مجم/100جم إلى موت جميع الجرذان الحوامل، بينما أدت المعاملة بالإلزيم المساعد كيو10 ثم بعقار فينلافاكسين بجرعتيه إلى الحد من هذه التغيرات مقارنة بالمجموعة المعاملة بعقار فينلافاكسين فقط.

نتائج الدراسات التي أجريت على الأجنة:

الدراسات القياسية:
• أظهرت نتائج البحث أن المعاملة بعقار فينلافاكسين بجرعة 0.25 مجم/100جم من وزن الجسم تسببت في حدوث نقص معنوي عالي جداً في معدل أوزان وأطوال الأجنة وطول الذيل مقارنة بالمجموعة الضابطة، وأدت المعاملة بالإلزيم المساعد كيو10 ثم المعاملة بعقار فينلافاكسين بجرعتيه إلى حدوث تحسن واضح في معدل أوزان وأطوال الأجنة مقارنة بالمجموعة المعاملة بعقار فينلافاكسين فقط.
• كما لوحظ من خلال نتائج البحث الحالي أن المعاملة بعقار فينلافاكسين بجرعة 0.25 مجم/100جم من وزن الجسم أدت إلى زيادة معدل الوفيات في الأجنة مقارنة بالمجموعة الضابطة بينما أدت المعاملة بالإلزيم المساعد كيو10 ثم بعقار فينلافاكسين بجرعتيه إلى الحد من هذه التغيرات مقارنة بالمجموعة المعاملة بعقار فينلافاكسين فقط.

الدراسات الظاهرية:
• بدراسة تأثير عقار فينلافاكسين بجرعة 0.25 مجم/100جم على الشكل الظاهري للأجنة لوحظ حدوث العديد من التشوهات الخارجية في الأجنة حيث اتضح اختلاف حجم الأجنة في الأم الواحدة، كما أصبح الجلد رقيقاً وشفافاً وظهر احتقان في الأوعية الدموية في منطقة الرأس والأذن وعديد من الجلطات الدموية تحت الجلد وظهر نمو في منطقة العين (البوز) تمثلت في ظهور الشفية الأمامية وتشوه الأطراف الأمامية والخلفية وتضخم في منطقة البطن وقوس الظهر بينما لوحظ أن المعاملة بالإلزيم المساعد كيو10 ثم بعقار فينلافاكسين بجرعتيه أدت إلى تحصص عدد الأجنة الحية حيث لم تسجل أي حالة وفاة.

دراسة الجهاز الهيكلي:
• أوضح من النتائج أن معاملة الجرذان الحوامل بعقار فينلافاكسين بجرعة 0.25 مجم/100جم من وزن الجسم أدت إلى زيادة عدد العظام غير معظمه سواء في الهيكل المحوري والهيكل الطرفي لأجنة الجرذان مقارنة بالمجموعة الضابطة.
• بينما أدت المعاملة بالإلزيم المساعد كيو10 ثم بعقار فينلافاكسين بجرعتيه إلى تحصص ملحوظ في تطعيم الجهاز الهيكلي مقارنة بالمجموعة المعاملة بعقار فينلافاكسين فقط.